Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
C4 Therapeutics Inc. is currently navigating 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct examiners and 3 distinct art units, showing a distribution of oversight for the company's pharmaceutical filings where the 5 pending actions are handled by 5 different individuals. This matching count of actions to examiners across 3 art units suggests that the company's immediate prosecution results are subject to a variety of individual examiner interpretations within a small number of technical groups.
The busiest examiner, HEITMEIER, KENDALL NICOLE, is managing 1 pending office action. Given that there are 5 pending actions and 5 distinct examiners, the workload is distributed so that each examiner handles 1 pending action. For the practitioner, this requires managing 5 separate examiner relationships and styles while maintaining a cohesive technical narrative across the 3 art units that comprise the company's current Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.6% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
| ELENISTE, PIERRE PAUL | 1 | 35.5% | +31.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18534395 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | AULAKH, CHARANJIT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516589 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | ELENISTE, PIERRE PAUL | 14d |
| 18797261 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | HEITMEIER, KENDALL NICOLE | — |
| 18576933 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1621 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18797261 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | HEITMEIER, KENDALL NICOLE | — | §112 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18774801 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | SHIAO, REI TSANG | — | §112DP | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18576933 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | HASTINGS, ALISON AZAR | 1627 | §103 | Final Rejection | — | Pending | Jan 05, 2024 |
| 18534395 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | AULAKH, CHARANJIT | 1621 | DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18516589 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | ELENISTE, PIERRE PAUL | 1622 | DP | Final Rejection | 14d | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial